

## *Curriculum Vitae*

**Ekkehard Grünig** Professor, Dr. med.

### **University Education**

2004 Habilitation Internal Medicine, Ruprecht-Karls University of Heidelberg  
1987 Doctorate Medicine, Ruprecht-Karls University of Heidelberg  
1979-1984 Studies of Medicine and Philosophy, Justus Liebig University Giessen (JLU)

### **Scientific Career**

Since 2011 Head of Division for Pulmonary Hypertension of the University of Heidelberg  
Since 2008 Professor of Internal Medicine, University of Heidelberg  
2004-2007 Ass. Prof. for Internal Medicine, Faculty of medicine, University of Heidelberg, Germany, Senior Physician  
1990-2003 Internship, Residency, Consultant for Internal Medicine and Cardiology, University of Heidelberg, Germany  
1988-1990 Doctoral candidate, Department of Cardiology, University of Heidelberg, Germany  
1984-1987 Research fellow, Hospital for Children, University of Mainz, Germany

### **Other Experience and Professional Memberships**

2012 Elected Speaker of the Pulmonary Hypertension Working Group of the German Society of Cardiology (DGK)  
2010 Member of the task force of the German comment to the European guidelines "Guidelines for the diagnosis and treatment of pulmonary hypertension"  
2010 Co-Speaker of the Pulmonary Hypertension Working Group of the German Society of Cardiology (DGK)  
2008 Elected Speaker of the Common Working Group of Pulmonary Hypertension Experts (Cardiology, Pediatric Cardiology and Pneumology) in Austria, Switzerland, Germany. In Germany, this working group is associated with the German Society of Cardiology, Pneumology and Pediatric Cardiology  
2006 Elected Speaker of the Pulmonary Hypertension Working Group of the German Society of Cardiology (DGK)  
Since 2006 Elected Member of the Steering-Committee of the European Project "Pulmotension"  
Since 2003 Member Task Force of the German Guidelines for Pulmonary Hypertension  
Since 2003 Interdisciplinary Working Group for Pulmonary Hypertension of the German Society of Cardiology, Pneumology, and Cardiology for Children  
2003 Task Force of Genetics of Pulmonary arterial hypertension, World Congress, Venice, Italy  
2002 – 2005 Co-Coordinator of the European trial "early diagnosis and genetics of primary pulmonary hypertension"  
Since 2003 Executive Board of René-Baumgart-Foundation, Germany  
Since 2001 Scientific Adviser Board of the PH e.V.  
Since 1998 Member of the self-help group of Pulmonary Hypertension PH e.V., Germany  
1988 – 1997 Coordinating Researcher of the German Registry for Patients with Dilated Cardiomyopathy, Heidelberg, Germany  
1984 – 1986 Faculty member of the University of Mainz as elected student representative

## Citation Record

*Publications: 399; Total citations: 14,681; h-index:58*

(Web of Science July 15<sup>th</sup>, 2024)

### 10 selected Publications

**Grünig E**, Jansa P, Fan F, Hauser JA, Pannaux M, Morganti A, Rofael H, Chin KM. Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension. *J Am Coll Cardiol.* 2024;83(4):473-484. doi: 10.1016/j.jacc.2023.10.045.

Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gombert-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, **Grünig E**, Kopeć G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M; STELLAR Trial Investigators. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. *N Engl J Med.* 2023;388(16):1478-1490. doi: 10.1056/NEJMoa2213558.

**Grünig E**, Eichstaedt C, Barberà JA, Benjamin N, Blanco I, Bossone E, Cittadini A, Coghlan G, Corris P, D'Alto M, D'Andrea A, Delcroix M, de Man F, Gaine S, Ghio S, Gibbs S, Gumbiene L, Howard LS, Johnson M, Jurevičienė E, Kiely DG, Kovacs G, MacKenzie A, Marra AM, McCaffrey N, McCaughey P, Naeije R, Olschewski H, Pepke-Zaba J, Reis A, Santos M, Saxer S, Tulloh RM, Ulrich S, Vonk Noordegraaf A, Peacock AJ. ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. *Eur Respir J.* 2019;53(2):1800332. doi: 10.1183/13993003.00332-2018.

Galiè N, Channick RN, Frantz RP, **Grünig E**, Jing ZC, Moiseeva O, Preston IR, Pulido T, Safdar Z, Tamura Y, McLaughlin VV. Risk stratification and medical therapy of pulmonary arterial hypertension. *Eur Respir J.* 2019;53(1):1801889. doi: 10.1183/13993003.01889-2018.

Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N, Olsson KM, Meyer K, Vizza CD, Vonk-Noordegraaf A, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Huscher D, Pittrow D, Rosenkranz S, **Grünig E**. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. *Eur Respir J.* 2017;50(2):1700740. doi: 10.1183/13993003.00740-2017.

Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachieri JL, **Grünig E**, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. *N Engl J Med.* 2015;373(9):834-44. doi: 10.1056/NEJMoa1413687.

Coghlan JG, Denton CP, **Grünig E**, Bonderman D, Distler O, Khanna D, Müller-Ladner U, Pope JE, Vonk MC, Doelberg M, Chadha-Boreham H, Heinzl H, Rosenberg DM, McLaughlin VV, Seibold JR; DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. *Ann Rheum Dis.* 2014;73(7):1340-9. doi: 10.1136/annrheumdis-2013-203301.

Ghofrani HA, Galiè N, Grimminger F, **Grünig E**, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ; PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. *N Engl J Med.* 2013;369(4):330-40. doi: 10.1056/NEJMoa1209655.

Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galiè N, Gómez-Sánchez MA, Grimminger F, **Grünig E**, Hassoun PM, Morrell NW, Peacock AJ, Satoh T, Simonneau G, Tapson VF, Torres F, Lawrence D, Quinn DA, Ghofrani HA. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. *Circulation.* 2013;127(10):1128-38. doi: 10.1161/CIRCULATIONAHA.112.000765.

Mereles D, Ehlken N, Kreuzer S, Ghofrani S, Hoeper MM, Halank M, Meyer FJ, Karger G, Buss J, Juenger J, Holzpfel N, Opitz C, Winkler J, Herth FF, Wilkens H, Katus HA, Olschewski H, **Grünig E**.

Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. *Circulation.* 2006;114(14):1482-9. doi: 10.1161/CIRCULATIONAHA.106.618397.